Compare FJET & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FJET | XOMA |
|---|---|---|
| Founded | 2022 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.1M | 308.6M |
| IPO Year | N/A | N/A |
| Metric | FJET | XOMA |
|---|---|---|
| Price | $6.42 | $29.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $60.60 |
| AVG Volume (30 Days) | ★ 983.7K | 102.7K |
| Earning Date | 04-30-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.95 |
| Revenue Next Year | N/A | $6.20 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.51 | $18.40 |
| 52 Week High | $28.56 | $39.92 |
| Indicator | FJET | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 63.57 |
| Support Level | $5.94 | $29.07 |
| Resistance Level | $8.46 | $35.17 |
| Average True Range (ATR) | 0.86 | 1.52 |
| MACD | 0.03 | 0.31 |
| Stochastic Oscillator | 5.87 | 73.97 |
Starfighters Space Inc is a commercial aerospace company based at NASA's Kennedy Space Center in Florida. The company operates supersonic aircraft capable of sustained Mach 2 flight and configured to carry payloads to high altitudes for air launch to space. Its activities include air launch operations, pilot and space flight training, support research, hypersonic testing, and other aerospace development programs. The company provides commercial space services and related aerospace capabilities.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.